Atlas Trials

A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy

Clinical trial NCT05337553 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05337553
Sponsor
Biohaven Pharmaceuticals, Inc.
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Spinal Muscular AtrophyNeuromuscular DiseasesSMA
Start date
2022-07-06
Primary completion
2024-09-25
Enrollment
269

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.